MedinCell S.A. (EPA:MEDCL)
France · Delayed Price · Currency is EUR 16.94
+0.05 (0.30%)
Sep 5, 2025, 5:36 PM CET
MedinCell Revenue
In the fiscal year ending March 31, 2025, MedinCell had annual revenue of 27.73M EUR with 132.12% growth. MedinCell had revenue of 18.29M in the half year ending March 31, 2025, with 207.64% growth.
Revenue
27.73M
Revenue Growth
+132.12%
P/S Ratio
20.22
Revenue / Employee
211.66K
Employees
131
Market Cap
560.58M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 27.73M | 15.78M | 132.12% |
| Mar 31, 2024 | 11.95M | -1.71M | -12.52% |
| Mar 31, 2023 | 13.66M | 5.32M | 63.77% |
| Mar 31, 2022 | 8.34M | 152.00K | 1.86% |
| Mar 31, 2021 | 8.19M | 2.19M | 36.43% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 27.24B |
| Sanofi | 45.74B |
| Sartorius Stedim Biotech | 2.90B |
| bioMérieux | 4.12B |
| Eurofins Scientific SE | 7.14B |
| Ipsen | 3.76B |
| ABIVAX Société Anonyme | 10.59M |
| Virbac | 1.40B |
MedinCell News
- 7 months ago - Teva Pharmaceuticals reports completion of phase 3 trial for Olanzapine LAI in Schizophrenia - Seeking Alpha